William Maich

William Maich

Auto-generated profile, based on publicly available information

William Maich

McMaster University 1 Department of Biochemistry and Biomedical Sciences Hamilton, Canada

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
WMWilliam T. Maich
William T. Maich
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
APAnish Puri
Anish Puri
MRMartin A. Rossotti
Martin A. Rossotti
SGShan Grewal
Shan Grewal
Sheila SinghSheila Singh
Sheila Singh
Glioblastoma (GBM) comprises nearly 15% of primary central nervous system (CNS) tumors and 50% of malignant primary CNS tumors worldwide. Considerable tumoral heterogeneity exists in GBM, leading to inefficacy of current treatments and the absence of meaningful improvements in frontline therapies in the past 20 years. Through multiomic analysis of patient-derived primary and recurrent GBM cell lines, we identified the urokinase plasminogen activator receptor (uPAR) as a protumorigenic marker of putative brain tumor–initiating cells and a potential therapeutic target. We found that genetic disruption of uPAR expression impaired protumorigenic characteristics in vitro and in vivo, highlighting its biological role in tumorigenesis. We then generated uPAR-specific chimeric antigen receptor (CAR) T cells, which demonstrated potent antitumor activity in recurrent GBM patient–derived xenograft models. In addition to direct tumor cell killing, we found that uPAR is expressed on GBM-associated macrophages, enabling uPAR CAR T cells to target both GBM itself and cells in the tumor microenvironment. Together, these data illustrate the potency and therapeutic potential of targeting uPAR in GBM.

5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
Normalized gRNA read counts for chemoradiogenetic CRISPR-Cas9 screen in GBM model BT935, related to figure 2B

5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
A) Immunoblotting of FEN1 protein in GSCs after knockout of FEN1 or AAVS1 (control), related to figure 2C and 2D. B) Immunoblotting of FEN1 protein in GSCs after knockdown of FEN1 or GFP (control), related to figure 2E.

5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
Sensitivity to FEN1 inhibition extends to TMZ sensitization. A, Cell viability assays of GSC and NSC lines exposed to increasing concentrations of FEN1 inhibitor over 7 days. Data are represented as mean ± SE; n = 4 experimental replicates. B, Cell viability assays of NSC, FEN1i-resistant, and FEN1i-sensitive GSC lines exposed to DMSO (control), 25 μmol/L TMZ, 30 μmol/L FEN1i, or combination (TMZ and FEN1i). Dashed lines represent expected viability under combination treatment. Data are represented as mean ± SE; n = 4 experimental replicates. C and D, Synergy assays between TMZ and FEN1 inhibitor in (C) FEN1i-resistant and (D) FEN1i-sensitive GBM models. Colors correspond to Bliss excess synergy scores, wherein more positive values indicate stronger synergy; n = 4 experimental replicates. ns, not statistically significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

1 October 2026 in Cancer Research Communications
Verified
Journal Article
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
Glioblastoma (GBM) is an aggressive brain tumor characterized by therapy resistance and recurrence. GBM stem cells (GSC) are key drivers of tumor maintenance, therapeutic resistance, and relapse, but targeting them remains clinically elusive due to their overlap with normal neural stem cells (NSC) and a lack of actionable vulnerabilities. To identify selective vulnerabilities in GSCs, we performed genome-wide CRISPR-Cas9 loss-of-function screening across patient-derived GSC models under standard-of-care treatment conditions. We identified flap endonuclease 1 (FEN1), a key enzyme in DNA replication and base excision repair, as an essential gene for GSC survival, with enhanced dependency in the context of temozolomide (TMZ) treatment. Genetic knockdown of FEN1 impaired GSC proliferation and self-renewal and extended survival in a patient-derived xenograft model. Pharmacologic inhibition of FEN1 using a small-molecule inhibitor revealed selective cytotoxicity in highly aggressive and recurrent GBM models while sparing NSCs. Notably, FEN1 inhibition synergized with TMZ to induce DNA double-strand breaks and potentiate cell death only in a subset of GSCs sensitive to FEN1 inhibition. Mechanistically, single-cell transcriptomics revealed that FEN1 expression correlates with programs linked to proliferation, stemness, and DNA damage repair, underscoring its role in maintaining the treatment-refractory phenotype. Our findings identify FEN1 as a selective vulnerability in aggressive, proliferative GSCs. FEN1 inhibition not only impairs GSC viability but also restores sensitivity to TMZ in treatment-resistant models, offering a strategy for salvage therapy in recurrent GBM. These results support the development of FEN1-targeted therapies and lay the foundation for a biomarker-guided approach to overcoming chemoresistance in GBM. Significance: GBM is a lethal brain tumor driven by therapy-resistant GSCs. We identified FEN1 as a selective vulnerability of GSCs that promotes TMZ resistance. FEN1 inhibition disrupts GSC self-renewal, restores TMZ sensitivity, and spares healthy NSCs, establishing FEN1 as a precision neuro-oncology target.

5 October 2026
Verified
Other
Open access
BBBenjamin Brakel
Benjamin Brakel
DMDillon McKenna
Dillon McKenna
APAnish Puri
Anish Puri
MSMuhammad Vaseem Shaikh
Muhammad Vaseem Shaikh
MSManoj Singh
Manoj Singh
Sheila SinghSheila Singh
Sheila Singh
ClusterProfiler analysis of conditional GIs (drugZ FDR < 0.05) from all screens, related to supplementary figure 2B